Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine > News > A step forward in prostate cancer screening optimisation
  • News

A step forward in prostate cancer screening optimisation

  • 26 February 2020
  • Elena Riboldi
A step forward in prostate cancer screening optimisation
Total
0
Shares
0
0
0
0
0

A single prostate-specific antigen (PSA) measurement in midlife may help to personalise prostate cancer screening, resulting in a reduced risk of overdiagnosis and overtreatment of indolent cancers. The authors of the study just published in JAMA Network Open came to this conclusion after finding that in a cohort of nearly 11,000 man aged 55 to 60 years, baseline PSA level correlated with long-term risk of clinically significant prostate cancer.

This study is likely to re-open the debate about the utility of PSA measurement as a screening tool. Introduced in the 1990s, it enjoyed wide acceptance until recent years, when its significance has been called into question. “Until a more accurate biomarker is identified, PSA remains the best screening tool available for early prostate cancer diagnosis” stated Evan Kovac, urologist at Montefiore Medical Center (Bronx, New York) and first author of the article. “Therefore, it is imperative to improve the detection of clinically significant prostate cancer while minimizing overdiagnosis and overtreatment through a more nuanced approach to PSA screening.”

The study consisted in a secondary analysis of a cohort of 10,968 men aged 55 to 60 years enrolled in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. The risk of being diagnosed with a clinically significant prostate cancer during 13 years of follow-up was lower among men with a baseline PSA level less than 0.49 ng/mL and higher among men with a baseline level more than 2.00 ng/mL. Of note, 83% of participants had baseline PSA levels less than 2.00 ng/mL.

“At a time when the concern regarding the overdiagnosis and overtreatment of indolent prostate cancer has led to intense scrutiny of the value of PSA levels as an effective screening tool, our data on the increasing risks associated with higher baseline PSA levels can be used to determine the optimal prostate cancer screening strategy for individual patients – Kovac explained – The low 13-year actuarial risk of a clinically significant prostate cancer diagnosis in middle-aged men with a baseline PSA level less than 2.00 ng/mL suggests that men younger than 60 years with PSA levels of 1.00 to 1.99 ng/mL can undergo less intensive screening than men with higher baseline PSA levels. Men with baseline PSA levels less than 1.00 ng/mL may wish to discontinue screening.” Data from this study may be used to inform patients for shared decision-making.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • PSA
  • screening
Elena Riboldi

Previous Article
  • Profiles

Chiara Gasparotto – winning the case for better access to radiotherapy

  • 11 February 2020
  • Peter McIntyre
View Post
Next Article
  • News

More evidence-based info on off-patent oncology drugs

  • 2 March 2020
  • Editorial Staff
View Post
You May Also Like
View Post
  • News

Antidepressants Show Potential to  Fight Cancer

  • Janet Fricker
  • 9 September 2025
View Post
  • News

CancerWorld #107 (September 2025)

  • Yeva Margaryan
  • 5 September 2025
View Post
  • ESCO Contest
  • News

ESO College Voices Contest 2025: Social media – friend or foe for cancer patients? – Winners Announced

  • Yeva Margaryan
  • 31 August 2025
View Post
  • News

Six Months of CancerWorld Under p53: A Report of Renewal, Responsibility, and Reach

  • Yeva Margaryan
  • 19 August 2025
View Post
  • News

CancerWorld #106 (August 2025)

  • Yeva Margaryan
  • 15 August 2025
View Post
  • Articles
  • Medicine
  • News

Cancer Neuroscience: How Neurons Fuel Tumor Growth, and What it Means for Therapy

  • Sophie Fessl
  • 12 August 2025
View Post
  • News

BRCA1/BRCA2 Mutations Carriers at Greater Risk for Anaplastic Large Cell Lymphoma Associated with Breast Implants

  • Janet Fricker
  • 12 August 2025
View Post
  • News

How a Simple Photo Can Help Predict Survival in Cancer Patients: The FaceAge AI

  • Janet Fricker
  • 12 August 2025
search
CancerWorld #106 Download CancerWorld #105 Download CancerWorld #105 Download CancerWorld #104 Download CancerWorld #103 Download CancerWorld #102 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Antidepressants Show Potential to  Fight Cancer
    • 9 September 2025
  • CancerWorld #107 (September 2025)
    • 5 September 2025
  • ESO College Voices Contest 2025: Social media – friend or foe for cancer patients? – Winners Announced
    • 31 August 2025
  • Six Months of CancerWorld Under p53: A Report of Renewal, Responsibility, and Reach
    • 19 August 2025
  • CancerWorld #106 (August 2025)
    • 15 August 2025
Article
  • Princess Dina: The Voice for The Voiceless
    • 4 September 2025
  • Patrick Soon-Shiong: He Who Speaks for the People
    • 4 September 2025
  • I Am Alive: Letter to Oncologists
    • 1 September 2025
Social

Would you follow us ?

Contents
  • Princess Dina: The Voice for The Voiceless
    • 4 September 2025
  • Patrick Soon-Shiong: He Who Speaks for the People
    • 4 September 2025
  • I Am Alive: Letter to Oncologists
    • 1 September 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.